Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients
Abstract
Secondary hyperparathyroidism is a common complication in patients with end-stage renal disease. It has been associated with increased cardiovascular events and mortality. Traditional therapy has been based on vitamin D analogs and phosphate binders; but these therapies often do not control secondary hyperparathyroidism, particularly in peritoneal dialysis patients for whom phosphate clearances are limited and intravenous vitamin D is impractical. Cinacalcet, a calcimimetic, suppresses parathormone secretion by interacting with the calcium-sensing receptor on the surface of parathyroid gland cells. The resulting suppression of parathyroid hormone secretion produces a reduction in serum phosphate level and CaxPO 4 product. The present paper reviews the efficacy of cinacalcet in the management of secondary hyperparathyroidism in peritoneal dialysis patients.
Related Papers
- → Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism(2005)172 cited
- → The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review(2015)26 cited
- → Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control(2014)29 cited
- → Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease(2005)18 cited